Dashboard
1
Weak Long Term Fundamental Strength with a 6.62% CAGR growth in Operating Profits over the last 5 years
2
Poor long term growth as Net Sales has grown by an annual rate of 7.08% and Operating profit at 6.62% over the last 5 years
3
Flat results in Jun 25
4
With ROCE of 7.08%, it has a very attractive valuation with a 0.80 Enterprise value to Capital Employed
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 39,160 Million (Small Cap)
9.00
NA
0.00%
0.45
7.88%
0.86
Revenue and Profits:
Net Sales:
12,859 Million
(Quarterly Results - Jun 2025)
Net Profit:
543 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
7.26%
0%
7.26%
6 Months
33.1%
0%
33.1%
1 Year
13.38%
0%
13.38%
2 Years
2.31%
0%
2.31%
3 Years
74.82%
0%
74.82%
4 Years
70.01%
0%
70.01%
5 Years
36.14%
0%
36.14%
Fuji Pharma Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.08%
EBIT Growth (5y)
6.62%
EBIT to Interest (avg)
45.26
Debt to EBITDA (avg)
2.68
Net Debt to Equity (avg)
0.46
Sales to Capital Employed (avg)
0.63
Tax Ratio
20.55%
Dividend Payout Ratio
18.00%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.78%
ROE (avg)
8.22%
Valuation key factors
Factor
Value
P/E Ratio
9
Industry P/E
Price to Book Value
0.70
EV to EBIT
11.27
EV to EBITDA
6.14
EV to Capital Employed
0.80
EV to Sales
1.09
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
7.08%
ROE (Latest)
7.95%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
12,859.00
11,095.00
15.90%
Operating Profit (PBDIT) excl Other Income
2,027.00
2,031.00
-0.20%
Interest
95.00
66.00
43.94%
Exceptional Items
6.00
-640.00
100.94%
Consolidate Net Profit
543.00
296.00
83.45%
Operating Profit Margin (Excl OI)
82.50%
94.80%
-1.23%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 15.90% vs -14.65% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 83.45% vs -70.13% in Mar 2025
Annual Results Snapshot (Consolidated) - Sep'24
Sep'24
Sep'23
Change(%)
Net Sales
46,138.00
40,889.00
12.84%
Operating Profit (PBDIT) excl Other Income
7,561.00
6,882.00
9.87%
Interest
196.00
121.00
61.98%
Exceptional Items
1,345.00
244.00
451.23%
Consolidate Net Profit
6,147.00
3,435.00
78.95%
Operating Profit Margin (Excl OI)
84.10%
94.40%
-1.03%
USD in Million.
Net Sales
YoY Growth in year ended Sep 2024 is 12.84% vs 15.42% in Sep 2023
Consolidated Net Profit
YoY Growth in year ended Sep 2024 is 78.95% vs 27.36% in Sep 2023
About Fuji Pharma Co., Ltd. 
Fuji Pharma Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






